Imiquimod-d9

Category	Herpes simplex Virus (HSV)
CAS	2712126-48-0
Description	Imiquimod-d9 (R 837-d9) is the deuterium labeled Imiquimod. Imiquimod (R 837), an immune response modifier, is a selective toll like receptor 7 (TLR7) agonist. Imiquimod exhibits antiviral and antitumor effects in vivo. Imiquimod can be used for the research of external genital, perianal warts, cancer and COVID-19.

Quotation Now

Synonyms	Imiquimod-d9\|HY-B0180S1\|CS-0377646\|1-(2-(methyl-d3)propyl-1,1,2,3,3,3-d6)-1H-imidazo[4,5-c]quinolin-4-amine
Molecular Weight	249.36
Molecular Formula	C14H16N4
Canonical SMILES	CC(C)CN1C=NC2=C1C3=CC=CC=C3N=C2N
Purity	≥98% (HPLC)
Solubility	In vitro: 10 mM in DMSO
Appearance	Solid powder
Storage	Store at -20°C
Complexity	294
Exact Mass	249.193987241
In Vitro	Stable heavy isotopes of hydrogen, carbon, and other elements have been incorporated into drug molecules, largely as tracers for quantitation during the drug development process. Deuteration has gained attention because of its potential to affect the pharmacokinetic and Metabolic profiles of drugs.
In Vivo	In animal models, imiquimod stimulates the innate immune response by increasing NK cell activity, activating macrophages to secretecytokines and nitric oxide, and inducing proliferation and differentiation of B lymphocytes. Imiquimod stimulates the innate immune response through induction, synthesis, and release of cytokines, including interferon-a (IFN-α), interleukin (IL)-6, and tumour necrosis factor (TNF)-α.
Target	Toll-like Receptor (TLR); Autophagy; SARS-CoV; HSV
XLogP3-AA	2.6